Invention Grant
- Patent Title: Anti-CD28 humanized antibodies
- Patent Title (中): 抗CD28人源化抗体
-
Application No.: US14326119Application Date: 2014-07-08
-
Publication No.: US09562098B2Publication Date: 2017-02-07
- Inventor: Caroline Mary , Nicolas Poirier , Bernard Vanhove
- Applicant: Effimune , Institut National de la Sante et de la Recherche Medicale (INSERM)
- Applicant Address: FR Nantes FR Paris
- Assignee: OSE Immunotherapeutics,Institut National de la Sante et de la Recherche Medicale (INSERM)
- Current Assignee: OSE Immunotherapeutics,Institut National de la Sante et de la Recherche Medicale (INSERM)
- Current Assignee Address: FR Nantes FR Paris
- Agency: Morgan, Lewis & Bockius LLP
- Priority: EP10290080 20100218; EP10290389 20100713
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K47/48 ; A61K39/00
Abstract:
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Public/Granted literature
- US20150071916A1 Anti-CD28 Humanized Antibodies Public/Granted day:2015-03-12
Information query
